Abstract 3068
Background
Current guidelines recommend cardiac function monitoring every 3 months in patients receiving trastuzumab, however evidences for optimal cardiac surveillance strategy are lacking. The aim of this study is to identify risk factors and to characterize clinical patterns of trastuzumab related cardiac dysfunction(TRCD) within 1 year of treatment in patients with breast cancer.
Methods
We identified and reviewed consecutive patients with breast cancer received trastuzumab and adequate cardiac monitoring (baseline and subsequent cardiac echocardiogram at least every 4 months) between Jan 2010 - Apr 2017 at a single center. TRCD were defined as an absolte decrease of ejection fraction(EF) ≥15% or ≥ 10% to below the lower limit of normal.
Results
Among 364 patients(median age 51 years), TRCD was developed in 33 patients (9.3%). Median time from trastuzumab to TRCD was 6.3 months(range 2.6-12.3). Incidence of TRCD was significantly higher in patients with prior anthracycline (12.1% vs. 5.1%, p = 0.026). In 20 out of 33 patients (60.6%), TRCD was diagnosed within the first 6 months of trastuzumab. Earlier TRCD was significantly associated with prior anthracycline (72% vs. 25%, p = 0.035). Among the patients with later TRCD development after 9 months of trastuzumab (n = 13), absolute EF decrease >5% in the first 6 months preceded in 10 patients (76.9%). Incidence of later TRCD was significantly lower in patients whose absolute EF decrease < =5% in the first 6 months (2.1%) than in whom with more than 5% of absolute EF decrease (11.8%).
Conclusions
TRCD development occurs earlier within the first 6 months of trastuzumab in patients with prior anthracycline use. The degree of absolute EF decrease in the first 6 months can predict later development of TRCD. Therefore, cardiac monitoring for the first 6 months of trastuzumab treatment should not be missed, especially in whom with prior exposure to anthracyclie. Adaptive less frequent cardiac surveillance strategy after 6 months may be considered in patients without significant EF change.
Clinical trial identification
Legal entity responsible for the study
Hee Kyung Ahn.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract